Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Hypertension

SGLT2 inhibitors: not just another glucose-lowering agent

Nature Reviews Nephrology volume 12, pages 128–129 (2016)Cite this article

Subjects

The effects of SGLT2 inhibitors on lowering blood pressure are well characterized, but data now demonstrate their enhanced blood pressure-lowering capacity when combined with dual antihypertensive therapy. Specifically, blood pressure was markedly reduced when dapagliflozin was administered to patients receiving a renin–angiotensin system blocker plus a calcium antagonist or β-blocker.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Oliva, R. V. & Bakris, G. L. Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors. J. Am. Soc. Hypertens. 8, 330–339 (2014).

    Article  CAS  Google Scholar 

  2. Lewington, S. et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360, 1903–1913 (2002).

    Article  Google Scholar 

  3. Bakris, G. & Cherney, D. SGLT-2 inhibitors for type 2 diabetes: renal and urinary issues. Renal & Urology News [online], (2015).

    Google Scholar 

  4. Baker, W. L. et al. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J. Am. Soc. Hypertens. 8, 262–275.e9 (2014).

    Article  CAS  Google Scholar 

  5. Bonner, C. et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat. Med. 21, 512–517 (2015).

    Article  CAS  Google Scholar 

  6. Zinman, B. et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373, 2117–2128 (2015).

    Article  CAS  Google Scholar 

  7. Tikkanen, I. et al. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care 38, 420–428 (2015).

    Article  CAS  Google Scholar 

  8. Weber, M. et al. Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, Phase 3 study. Lancet Diabetes Endocrinol. http://dx.doi.org/10.1016/S2213-8587(15)00417-9 (2015).

  9. Lambers Heerspink, H. J., de Zeeuw, D., Wie, L., Leslie, B. & List, J. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes. Metab. 15, 853–862 (2013).

    Article  CAS  Google Scholar 

  10. Bakris, G. L., Iyengar, M., Lukas, M. A., Ordronneau, P. & Weber, M. A. Effect of combining extended-release carvedilol and lisinopril in hypertension: results of the COSMOS study. J. Clin. Hypertens. (Greenwich) 12, 678–686 (2010).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, ASH Comprehensive Hypertension Center, Section of Endocrinology, Diabetes and Metabolism, The University of Chicago Medicine, Chicago, 5841 South Maryland Avenue, MC 1027, Chicago, 60637, Illinois, USA

    Hillel Sternlicht & George L. Bakris

Authors
  1. Hillel Sternlicht
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. George L. Bakris
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to George L. Bakris.

Ethics declarations

Competing interests

G.B. consults for Bayer, Boerhinger-Ingelheim, Takeda, AbbVie, Janssen, Merck, Astra-Zeneca and Relypsa. H.S. declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sternlicht, H., Bakris, G. SGLT2 inhibitors: not just another glucose-lowering agent. Nat Rev Nephrol 12, 128–129 (2016). https://doi.org/10.1038/nrneph.2015.217

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneph.2015.217

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing